Search In this Thesis
   Search In this Thesis  
العنوان
Efficacy of Simvastatin in Treating Patients with Traumatic Brain Injury using Amyloid Precursor protein as a marker for Axonal /
المؤلف
Mahran, Mokhtar Mostafa.
هيئة الاعداد
باحث / مختار مصطفي مهران
مشرف / ناجى سيد على
مشرف / عبير أحمد حسانين
مشرف / عـماد علام عبد النعيم
الموضوع
Anesthesia in neurology. Anesthesia.
تاريخ النشر
2017.
عدد الصفحات
156 p. :
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
التخدير و علاج الألم
تاريخ الإجازة
1/1/2017
مكان الإجازة
جامعة المنيا - كلية الطب - التخدير والعناية المركزة
الفهرس
Only 14 pages are availabe for public view

from 176

from 176

Abstract

Forty patients of either sex, aged between 18-60 years old with acute moderate TBI (GCS 9-12) admitted to ICU of Minia University Hospital between May 2015 to May 2016, were enrolled in this prospective randomized study.
The patients included in the study were allocated randomly to 2 groups 20 patients in each group. group (I) received standard care and medications of TBI protocol. (II) received simvastatin 80 mg in the first day then, 40 mg daily for 7 days in addition to standard care and medications of TBI protocol.
The aim of our study was to determine whether simvastatin administration after acute TBI could acutely influence APP measured in plasma. Also, to know whether the administration of simvastatin has neuroprotective effect.
The following variables were recorded; haemodynamics, duration of mechanical ventilation, ICU length of stay and mortality, APACHE II score at admission and discharge, GCS on admission, 1 hour, 24, 48, 72, 96, 120, 148, and 172 hours after admission, GOS at discharge, 3 months and 6 months after discharge and Serum level of APP on admission, 3rd and 5th day after admission.
Haemodynamics, length of stay in ICU, duration of mechanical ventilation and ICU mortality were comparable between groups.
APACHE II score at discharge was significantly lower in statin group when compared with the control group.
We found that patients received simvastatin showed improvement in GCS which was obvious at 3rd day of admission.
As regard to GOS, simvastatin treated patients had more favorable outcomes when compared to control group at discharge, 3 and 6 months after discharge.
By comparing the serum level of APP between the two groups, we found that there was significant reduction in the level of APP in patients received simvastatin when compared to the other group at 3rd and 5th day of admission. correlation done between GCS and level of APP and it demonstrated negative correlation between them.